Briacell Therapeutics Corp
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that… Read more
Briacell Therapeutics Corp (BCTX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of October 2025: -1.143x
Based on the latest financial reports, Briacell Therapeutics Corp (BCTX) has a cash flow conversion efficiency ratio of -1.143x as of October 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.69 Million) by net assets ($9.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Briacell Therapeutics Corp - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Briacell Therapeutics Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Briacell Therapeutics Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Briacell Therapeutics Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xbrane Biopharma AB
ST:XBRANE
|
-0.121x |
|
SynCore Biotechnology Co Ltd
TWO:4192
|
-0.028x |
|
Dr. Phone Fix Canada Corporation
V:DPF
|
N/A |
|
Gagasan Nadi Cergas Berhad
KLSE:0206
|
0.242x |
|
Elgi Rubber Company Limited
NSE:ELGIRUBCO
|
-0.092x |
|
Beyond Air Inc
NASDAQ:XAIR
|
-0.509x |
|
Iconic Worldwide Bhd
KLSE:9113
|
-0.018x |
|
Turnium Technology Group Inc.
V:TTGI
|
0.073x |
Annual Cash Flow Conversion Efficiency for Briacell Therapeutics Corp (2006–2025)
The table below shows the annual cash flow conversion efficiency of Briacell Therapeutics Corp from 2006 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-07-31 | $23.83 Million | $-39.07 Million | -1.639x | -118.54% |
| 2024-07-31 | $-3.73 Million | $-32.97 Million | 8.845x | +39.91% |
| 2023-07-31 | $-5.04 Million | $-31.89 Million | 6.322x | +627.54% |
| 2022-07-31 | $13.25 Million | $-15.87 Million | -1.198x | -319.15% |
| 2021-07-31 | $34.58 Million | $-9.89 Million | -0.286x | -166.16% |
| 2020-07-31 | $-3.60 Million | $-1.55 Million | 0.432x | -94.19% |
| 2019-07-31 | $-688.66K | $-5.12 Million | 7.434x | +241.81% |
| 2018-07-31 | $945.02K | $-4.95 Million | -5.242x | -105.75% |
| 2017-07-31 | $750.23K | $-1.91 Million | -2.548x | -27.07% |
| 2016-07-31 | $787.11K | $-1.58 Million | -2.005x | -95.86% |
| 2015-07-31 | $1.16 Million | $-1.19 Million | -1.024x | -100.29% |
| 2014-07-31 | $-1.13K | $-397.42K | 352.638x | +862188.34% |
| 2013-07-31 | $9.33 Million | $-381.80K | -0.041x | -7.25% |
| 2012-07-31 | $10.03 Million | $-382.74K | -0.038x | +32.46% |
| 2011-07-31 | $11.63 Million | $-656.68K | -0.056x | +74.43% |
| 2010-07-31 | $1.44 Million | $-318.63K | -0.221x | -42.45% |
| 2009-07-31 | $974.50K | $-151.05K | -0.155x | +36.89% |
| 2008-07-31 | $365.17K | $-89.68K | -0.246x | -25.01% |
| 2007-07-31 | $446.71K | $-87.76K | -0.196x | -1492.28% |
| 2006-07-31 | $79.82K | $1.13K | 0.014x | -- |